Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 192, Issue 1-2, Pages 157-170Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2007.08.004
Keywords
HIV-associated cognitive impairment; biomarkers; protcomics; CSF
Categories
Funding
- NCRR NIH HHS [RCMI-CRC-1P20RR11126, G12 RR003051, G12 RR003051-22, P20 RR011126, P20 RR011126-110020, P20 RR011126-110019] Funding Source: Medline
- NINDS NIH HHS [U54 NS043011, R01 NS034239-12, R01 NS034239, U54 NS043011-06, R37 NS36136, NINDS U54 NS4301, R01 NS34239] Funding Source: Medline
- PHS HHS [NCRR-RCMI G12 RR-03051] Funding Source: Medline
Ask authors/readers for more resources
Cognitive impairment remains a major complication of advanced human immunodeficiency virus (HIV) infection despite the widespread use of anti-retroviral therapy. Diagnosis is made by exclusion making biomarkers of great potential use. Thus, we used an integrated proteomics platform to assess cerebrospinal fluid protein profiles from 50 HIV-1 seropositive Hispanic women. Nine of 38 proteins identified were unique in those patients with cognitive impairment (Cl). These proteins were linked to cell signaling, structural function, and antioxidant activities. This work highlights, in a preliminary manner, the utility of proteomic profiling for biomarker discovery for HIV-1 associated cognitive dysfunction. Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available